123 related articles for article (PubMed ID: 27095361)
1. MammaPrint Reduces Breast Cancer Overtreatment.
Cancer Discov; 2016 Jun; 6(6):OF4. PubMed ID: 27095361
[TBL] [Abstract][Full Text] [Related]
2. Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.
Audeh W; Blumencranz L; Kling H; Trivedi H; Srkalovic G
Acta Med Acad; 2019 Apr; 48(1):18-34. PubMed ID: 31264430
[TBL] [Abstract][Full Text] [Related]
3. Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.
Havard R; Henry NL
Future Oncol; 2017 Dec; 13(28):2507-2510. PubMed ID: 29168654
[No Abstract] [Full Text] [Related]
4. Equivalence of MammaPrint array types in clinical trials and diagnostics.
Beumer I; Witteveen A; Delahaye L; Wehkamp D; Snel M; Dreezen C; Zheng J; Floore A; Brink G; Chan B; Linn S; Bernards R; van 't Veer L; Glas A
Breast Cancer Res Treat; 2016 Apr; 156(2):279-87. PubMed ID: 27002507
[TBL] [Abstract][Full Text] [Related]
5. Understanding tumor profiling and assessing treatment.
Hyams DM
Manag Care; 2008 Jul; 17(7 Suppl 7):4-8; discussion 17-8. PubMed ID: 19093336
[TBL] [Abstract][Full Text] [Related]
6. The present and future of gene profiling in breast cancer.
Espinosa E; Gámez-Pozo A; Sánchez-Navarro I; Pinto A; Castañeda CA; Ciruelos E; Feliu J; Vara JA
Cancer Metastasis Rev; 2012 Jun; 31(1-2):41-6. PubMed ID: 22124734
[TBL] [Abstract][Full Text] [Related]
7. Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
Mook S; Van't Veer LJ; Rutgers EJ; Piccart-Gebhart MJ; Cardoso F
Cancer Genomics Proteomics; 2007; 4(3):147-55. PubMed ID: 17878518
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling: decoding breast cancer.
de Snoo F; Bender R; Glas A; Rutgers E
Surg Oncol; 2009 Dec; 18(4):366-78. PubMed ID: 19879448
[TBL] [Abstract][Full Text] [Related]
9. Molecular advances in early breast cancer. Breast cancers are as diverse as the women who have them. Now experts are using gene-based information to tailor treatment.
Harv Womens Health Watch; 2009 Oct; 17(2):1-3. PubMed ID: 19998551
[No Abstract] [Full Text] [Related]
10. [Multi-gene assay profiling testing and individualized therapy in breast cancer].
Chen XS; Shen KW
Zhonghua Wai Ke Za Zhi; 2017 Feb; 55(2):99-103. PubMed ID: 28162207
[TBL] [Abstract][Full Text] [Related]
11. Individualizing therapeutic decision making in early-stage breast cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):41-2. PubMed ID: 17824559
[No Abstract] [Full Text] [Related]
12. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
13. MammaPrint Pre-screen Algorithm (MPA) reduces chemotherapy in patients with early-stage breast cancer.
Grant KA; Apffelstaedt JP; Wright CA; Myburgh E; Pienaar R; De Klerk M; Kotze MJ
S Afr Med J; 2013 Jul; 103(8):522-6. PubMed ID: 23885731
[TBL] [Abstract][Full Text] [Related]
14. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
15. Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.
Smyth L; Watson G; Walsh EM; Kelly CM; Keane M; Kennedy MJ; Grogan L; Hennessy BT; O'Reilly S; Coate LE; O'Connor M; Quinn C; Verleger K; Schoeman O; O'Reilly S; Walshe JM
Breast Cancer Res Treat; 2015 Oct; 153(3):573-82. PubMed ID: 26364296
[TBL] [Abstract][Full Text] [Related]
16. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
17. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
18. [A plea for selective use of the MammaPrint test].
de Boer M; Voogd AC; Tjan-Heijnen VC
Ned Tijdschr Geneeskd; 2017; 161():D1160. PubMed ID: 28401819
[TBL] [Abstract][Full Text] [Related]
19. [Tumor size and histological grading of stage 1 breast cancer. Prognostic and therapeutic significance].
Gundersen S; Bøhler P; Hannisdal E; Høst H
Tidsskr Nor Laegeforen; 1996 Jan; 116(2):222-5. PubMed ID: 8633328
[TBL] [Abstract][Full Text] [Related]
20. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
